Neuren Pharmaceuticals Ltd  

(Public, ASX:NEU)   Watch this stock  
Find more results for NEU
0.0000 (0.00%)
May 25 - Close
ASX data delayed by 20 mins - Disclaimer
Currency in AUD
Range 0.07 - 0.07
52 week 0.06 - 0.13
Open 0.07
Vol / Avg. 1.37M/2.19M
Mkt cap 123.62M
P/E     -
Div/yield     -
EPS -0.01
Shares 1.77B
Beta     -
Inst. own     -

Key stats and ratios

Q4 (Dec '15) 2015
Net profit margin -4106.63% -667.18%
Operating margin -4552.55% -759.16%
EBITD margin - -754.68%
Return on average assets -90.12% -68.68%
Return on average equity -107.95% -79.51%
CDP Score - -


Suite 501, 697 Burke Road, Camberwell
+61-3-90920480 (Phone)

Website links


Neuren Pharmaceuticals Limited (Neuren) is a biopharmaceutical company engaged in developing drugs for neurological disorders. The Company develops therapies for brain injury, neurodevelopmental and neurodegenerative disorders. Its drugs target symptoms resulting from acute traumatic brain injury, as well as symptoms of chronic conditions, such as Rett syndrome and Fragile X syndrome. Its products include NNZ-2566 and NNZ-2591. Its lead product, NNZ-2566 (Trofinetide), is in Phase II trial for the treatment of Rett syndrome, Fragile X syndrome, moderate to severe Traumatic Brain Injury (TBI) and Concussion. Trofinetide is an analog of a molecule, which is derived from insulin-like growth factor-1 (IGF-1) and occurs naturally in the brain. Its NNZ-2591 product is in Pre-clinical and Phase I trial for the treatment of other neurological conditions. Its subsidiaries include Hamilton Pharmaceuticals Inc. and Neuren Pharmaceuticals Inc.

Officers and directors

Richard Treagus Executive Chairman of the Board
Jon Charles Pilcher Chief Financial Officer, Company Secretary
Larry Glass Chief Science Officer, Executive Director
James Shaw Vice President - Clinical Operations
Joseph Horrigan Vice President - Clinical Development and Medical Affairs
Bruce Alan Hancox Independent Non-Executive Director
Trevor D. Scott Independent Non-Executive Director